Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBT: 2013-2025

Historic EBT for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$44.5 million.

  • Coherus Oncology's EBT rose 6.47% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year increase of 124.40%. This contributed to the annual value of $28.5 million for FY2024, which is 111.96% up from last year.
  • Latest data reveals that Coherus Oncology reported EBT of -$44.5 million as of Q3 2025, which was up 0.77% from -$44.9 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's EBT ranged from a high of $197.8 million in Q4 2024 and a low of -$172.9 million during Q1 2021.
  • Moreover, its 3-year median value for EBT was -$47.4 million (2025), whereas its average is -$31.6 million.
  • In the last 5 years, Coherus Oncology's EBT tumbled by 573.76% in 2021 and then soared by 348.34% in 2024.
  • Over the past 5 years, Coherus Oncology's EBT (Quarterly) stood at -$45.7 million in 2021, then dropped by 28.75% to -$58.9 million in 2022, then plummeted by 35.30% to -$79.7 million in 2023, then spiked by 348.34% to $197.8 million in 2024, then grew by 6.47% to -$44.5 million in 2025.
  • Its last three reported values are -$44.5 million in Q3 2025, -$44.9 million for Q2 2025, and -$47.4 million during Q1 2025.